首页> 外文期刊>American Journal of Cancer Research >CRISPR screen in cancer: status quo and future perspectives
【24h】

CRISPR screen in cancer: status quo and future perspectives

机译:CRISPR筛查癌症:现状和未来的观点

获取原文
       

摘要

Clustered regularly interspaced short palindromic repeats (CRISPR) system offers a powerful platform for genome manipulation, including protein-coding genes, noncoding RNAs and regulatory elements. The development of CRISPR screen enables high-throughput interrogation of gene functions in diverse tumor biologies, such as tumor growth, metastasis, synthetic lethal interactions, therapeutic resistance and immunotherapy response, which are mostly performed in vitro or in transplant models. Recently, direct in vivo CRISPR screens have been developed to identify drivers of tumorigenesis in native microenvironment. Key parameters of CRISPR screen are constantly being optimized to achieve higher targeting efficiency and lower off-target effect. Here, we review the recent advances of CRISPR screen in cancer studies both in vitro and in vivo , with a particular focus on identifying cancer immunotherapy targets, and propose optimizing strategies and future perspectives for CRISPR screen.
机译:集群定期间隙的短语重复(CRISPR)系统为基因组操作提供了强大的基因组平台,包括蛋白质编码基因,非编码RNA和调节元件。 CRISPR筛网的开发使得在不同肿瘤生物学中的基因功能的高通量审查,例如肿瘤生长,转移,合成致命相互作用,治疗性抗性和免疫疗法响应,主要在体外或移植模型中进行。 最近,已经开发了直接体内CRISPR屏幕,以识别天然微环境中肿瘤内酯的驱动因素。 CRISPR屏幕的关键参数不断得到优化,以实现更高的靶向效率和较低的偏移效果。 在这里,我们回顾了体外和体内癌症研究中CRISPR筛查的最新进展,特别关注鉴定癌症免疫治疗目标,并提出优化CRISPR屏幕的策略和未来的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号